AMP Announces Q2 Picks


We are pleased to announced two of our Q2 company picks for 2017: Paratek Pharmaceuticals (PRTK) and Selecta Biosciences (SELB) . Our followers are aware that we started positions in our hypothetical fund for PRTK on Feb 28 and SELB on March 2. Since then we have been steadily increasing our positions and are currently up +24.21% with PRTK and +7.14% with SELB.

Read our exclusive research reports for our first two Q2 2017 picks below and stay tuned for more of our Q2 picks:

Paratek Pharmaceuticals (PRTK)

Selecta Biosciences (SELB)

Best,

AMP Biotech Team


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon